Brainomix
Medical imaging company using artificial intelligence for the fast diagnosis and treatment of stroke victims.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | £14.0m Valuation: £80.0m | Series C | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 21 % | - | 12 % | 18 % | 78 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Brainomix is a healthcare technology company that specializes in developing AI-powered imaging solutions to improve stroke treatment. Founded in 2010 as a spin-out from the University of Oxford, Brainomix has grown to serve medical professionals globally, with its solutions being used in over 30 countries. The company focuses on creating imaging biomarkers—essentially, measurable indicators found in medical images—that help doctors make precise treatment decisions.
Brainomix's flagship product, e-Stroke, is a comprehensive suite of tools designed to assist clinicians throughout the entire stroke treatment process. This includes diagnosing, triaging, and transferring patients to ensure they receive the right treatment at the right time. The e-Stroke suite includes several key components:
1. **e-ASPECTS**: This tool automatically assesses the severity of a stroke by analyzing CT images, detecting large vessel occlusions (LVOs) and hyperdense volumes that may indicate bleeding. It provides exact and reliable results every time, aiding in quick and accurate diagnosis.
2. **e-CTA**: This component standardizes the assessment of blood flow in the brain using CT angiography scans. It automatically detects LVOs and provides visual aids to help doctors understand the timing of blood flow.
3. **e-CTP**: This tool helps visualize blood flow and tissue viability, providing crucial information for treatment decisions.
Brainomix operates in the healthcare market, specifically focusing on stroke care. Its clients include hospitals, clinics, and medical professionals who need advanced tools to improve patient outcomes. The company makes money by selling its AI-powered software solutions to these healthcare providers, often through licensing agreements or subscription models.
In summary, Brainomix leverages cutting-edge AI technology to enhance the speed and accuracy of stroke diagnosis and treatment, ultimately aiming to save lives and improve patient outcomes.
**Keywords**: AI-powered, imaging solutions, stroke treatment, healthcare, biomarkers, diagnosis, triage, CT images, medical professionals, University of Oxford.